Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”

Full Show: Bloomberg Daybreak: Australia (03/24)
25:02 - Bloomberg Daybreak: Australia hosted by Haidi Lun and Betty Liu. Guests include Thomas Wright, fellow at Lowy Institute, and John Athanasiou, chief executive officer at Redleaf Securities. (Source: Bloomberg)
  • Analyst Sen Sees Oil Above $60 If OPEC Extends Deal
  • Oil Down for 3rd Week, OPEC Meets in Kuwait
  • Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month